PROSTATE CANCER IN 2011: Redefining the therapeutic landscape for CRPC

    loading  Checking for direct PDF access through Ovid


2011 was a breakthrough year for the treatment of castration-resistant prostate cancer. The encouraging results of two large clinical trials were reported, as well as data identifying a number of promising new therapeutic targets. Bone-modulating agents continued to show potential for the prevention of skeletal events.

    loading  Loading Related Articles